COVID‐19‐related anxiety predicts somatic symptoms in the UK population by Shevlin, M. et al.
This is a repository copy of COVID 19 related anxiety predicts somatic symptoms in the ‐ ‐
UK population.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/162767/
Version: Published Version
Article:
Shevlin, M., Nolan, E., Owczarek, M. et al. (12 more authors) (2020) COVID 19 related ‐ ‐
anxiety predicts somatic symptoms in the UK population. British Journal of Health 
Psychology. ISSN 1359-107X 
https://doi.org/10.1111/bjhp.12430
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
British Journal of Health Psychology (2020)
© 2020 The Authors. British Journal of Health Psychology published
by John Wiley & Sons Ltd on behalf of British Psychological Society
www.wileyonlinelibrary.com
Brief-Report Covid-19
COVID-19-related anxiety predicts somatic
symptoms in the UK population
Mark Shevlin1 , EmmaNolan1, MarcinOwczarek1, Orla McBride1,
JamieMurphy1, JillyGibsonMiller2*, ToddK.Hartman2, Liat Levita2,
Liam Mason3, Anton P. Martinez2, Ryan McKay4, Thomas V. A.
Stocks2, Kate M. Bennett5, Philip Hyland6 and Richard P. Bentall2,5
1Ulster University, Coleraine, UK
2University of Sheffield, UK
3University College London, UK
4Royal Holloway, University of London, UK
5Liverpool University, UK
6Maynooth University, Ireland
This study aimed to estimate the association between anxiety associated with COVID-19
and somatic symptoms, using data from a large, representative sample (N = 2,025) of the
UK adult population. Results showed that moderate to high levels of anxiety associated
with COVID-19 were significantly associated with general somatic symptoms and in
particular with gastrointestinal and fatigue symptoms. This pattern of associations
remained significant after controlling for generalized anxiety disorder (GAD), pre-
existing health problems, age, gender, and income. This is the first evidence that anxiety
associated with COVID-19 makes a unique contribution to somatization, above and
beyond the effect of GAD.
Statement of contribution
What is already known on this subject?
Somatic symptoms are commonly reported in the general population, and many are medically
unexplained. There is also evidence that high levels of anxiety are associated with reporting more
somatic symptoms and increased impairment. Research evidence from previous infectious disease
pandemics, such as SARS, showed increased levels of anxiety in the general population during
quarantine, and this was associated with increased reporting of somatic symptoms.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
*Correspondence should be addressed to Dr Jilly Gibson Miller, Department of Psychology, The University of Sheffield, Floor G,
Cathedral Court, 1 Vicar Lane, Sheffield, S1 2LT, UK (email: jilly.gibson@sheffield.ac.uk).
DOI:10.1111/bjhp.12430
1
What does this study add?
During the current COVID-19 pandemic in the United Kingdom, there may be increased levels of
generalized anxiety in the general population, but theremay also be anxiety specifically associatedwith
COVID-19. This study is the first to show that there is a positive association between both generalized
anxiety and COVID-19 specific anxiety and the reporting of somatic symptoms. Indeed, COVID-19
specific anxiety explained unique variance in somatic symptoms after controlling for generalized
anxiety and other potential confounding variables.
It has previously been demonstrated that health pandemics have psychological
consequences. Studies of the psychological effects of severe acute respiratory syndrome
(SARS), which emerged in 2003, showed that PTSD symptoms, anxiety, and depression
were significantly associated with time spent in quarantine (Hawryluck et al., 2004). The
magnitude of the current quarantine measures imposed by the UK government are much
greater and stricter than those imposed in any previous infectious disease pandemic, and
negative psychological consequences for the general population are expected. There is
recent evidence that the levels of anxiety and depression in the UK population may be
elevated compared to pre-pandemic levels (Shevlin et al., 2020), and this is consistent
with research findings from other countries (Huang & Zhao, 2020).
To date, one area that has received little attention in the context of the current
pandemic is the association between anxiety and somatic symptoms. There is evidence
from general population studies that somatic symptoms are frequently reported and
positively associated with depression and anxiety (Haug et al., 2004; Hinz et al., 2017). A
recent study in the Hubei province and non-endemic provinces of China (Yuan et al.,
2020) found associations between somatic symptoms and levels of anxiety during the first
2 weeks of the COVID-19 outbreak. As anxiety scores decreased, there was a
corresponding decrease in somatic symptoms.
The primary aim of this study was to examine whether self-reported anxiety related to
the COVID-19 pandemic predicted scores on a validated, multi-dimensional measure of
somatic symptoms in a representative UK adult population sample. In addition, it was
predicted that COVID-19 anxiety would remain significantly associated with somatic
symptoms after controlling for multiple confounding variables including age, gender,
income, pre-existing health problems, and generalized anxiety disorder (GAD).
Methods
Participants
Data collection started on 23March 2020, 52 days after the first confirmedCOVID-19 case
in the United Kingdom and was completed on 28 March 2020. Participants (N = 2,025)
were recruited from an online research panel using stratified quota sampling to ensure
that the sample characteristics of sex, age, household income (quintiles), and region of the
United Kingdommatched the UK population. Subsequent checks ensured that they were
also representative of the population in ethnicity, number of people in household, and
other important demographic characteristics (for details on recruitment and sample, see
McBride et al., 2020).
Measures
Self-reported gender and age were recorded.
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Income
Participants were asked ‘Please choose from the following options to indicate your
approximate gross (before tax is taken away) household income in 2019 (last year).
Include income from partners and other family members living with you and all kinds of
earnings including salaries and benefits’; they had to choose one of 5 categories ranging
from ‘no income to £15,490 per year’ to ‘£57,931 or more per year’.
Pre-existing health problems
Participants were asked ‘Were you diagnosed with a health condition (e.g., heart or lung
disease; diabetes; cancer) before December 31st 2019 (i.e., before the start of the
coronavirus COVID-19 outbreak)?’, and the response options were ‘Yes’ (1) and ‘No’ (0).
COVID-19-related anxiety
The survey included a question ‘How anxious are you about the coronavirus COVID-19
pandemic?’; participantswereprovidedwith a ‘slider’ (electronic visual analogue scale) to
indicate their degree of anxiety with ‘0’ and ‘100’ at the left- and right-hand extremes,
respectively, and 10-point increments. This produced continuous scores ranging from 0
to 100 with higher scores reflecting higher levels of COVID-19-related anxiety.
Generalized anxiety
Symptoms of GAD were measured using the Generalized Anxiety Disorder 7-item Scale
(GAD-7: Spitzer et al., 2006); participants were categorized as screening positive for GAD
if they scored above the cut-off score of ≥10. The GAD-7 has been shown to produce
reliable and valid scores in community studies, and the reliability in the current sample
was high (a = .94).
Somatic symptoms
Somatic symptoms were measured using the Patient Health Questionnaire (PHQ-15:
Kroenke et al., 2002). The PHQ-15 is a 15-item self-report measure that asks participants
the degree to which they have been bothered by physical health problems in the last
2 weeks (items are rated on a 3-point Likert scale ranging from 0 [not bothered at all] to 2
[bothered a lot]). The scalewas scored using themulti-dimensional approachproposedby
Cano-Garcıa et al. (2020); following these authors, we excluded the ‘menstrual problems’
item, which contains gender-specific content, and the ‘fainting spells’ item, which has
previously been found tohave lowendorsement rates. The total scale scores and subscales
reflecting pain symptoms, gastrointestinal symptoms, cardiopulmonary symptoms, and
fatigue symptomswere used. Multiple previous studies attest to the reliability and validity
of the PHQ-15 (Hinz et al., 2017).
Analysis
Scores on theCOVID-19 anxiety variablewere categorized into quintiles, and the quintiles
were dummy-codedwith the lowest quintile used as the reference category. This allowed
to test for non-linear associations. Regression models were used to estimate the
relationship between the COVID-19 anxiety quintiles and the PHQ-15 subscales (pain,
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gastrointestinal, cardiopulmonary, and fatigue). Model 1 included the four dummy-coded
COVID-19 anxiety variables as predictors of the four PHQ-15 subscales; the four subscale
scores were included in a singlemodel. The regression coefficient for each dummy-coded
variable is interpreted as the difference in means between that quintile and the lowest
quintile. Model 1 was also run separately with the total PHQ-15 summed scale score
replacing the subscales. Model 2 included the covariates (age, gender, income, pre-
existing health problems, and GAD) as predictors, and this model was estimated with the
subscales as dependent variables andwith the total scale score as the outcomevariable. All
four models were specified and estimated using Mplus 8.1 (Muthen, & Muthen, 2018)
using robust maximum likelihood.
Results
Descriptive statistics for all the study variables are presented in Table 1. The income
bands were approximately equal (£0 – 15,490 per year [n = 410, 20.2%]; £15,491 –
£25,340 per year [n = 410, 20.2%]; £25,341 – £38,740 per year [n = 385, 19.0%]; £38,741
– £57,930 per year [n = 410, 20.2%]; and £57,931 or more per year [n = 410, 20.2%]).
COVID-19 anxietywas positively correlatedwith all of the somatic symptom subscales
and the total scale score. The somatic symptom subscales were all highly and positively
correlated with each other, and the correlations with GAD were higher than for the
COVID-19 anxiety scores (see Table 1). Table 2 shows the estimates from the regression
models. A significant proportion of variance was explained in each of the somatic
symptom subscales with the exception of cardiopulmonary symptoms. A similar pattern
of results emerged across all subscales and the total scale score: The effects for quintiles 2
to 4 were significant, but the magnitude was small compared to the effects for the 5th
quintile. Rather than a linear increase, there appears to be an increase in quintiles 2, 3, and
4 compared to the first quintile, and then a much larger effect for the 5th quintile. For
Model 2 that included the control variables, the pattern of results for COVID-19 anxiety
was similar albeit themagnitude of the effects was, expectedly, attenuated. The estimates
for the 5th quintile all remained statistically significant. The effects for GAD-7 were all
large, positive, and statistically significant.
Discussion
This study sought to determine whether self-reported COVID-19 anxiety levels were
associated with increased somatic symptoms within a representative sample of the UK
adult population. Our findings indicated that having COVID-19 anxiety scores in the 2nd
or higher quintile was associated with increased somatic symptoms, suggesting a
threshold above which the chances of experiencing somatic symptoms are greatly
enhanced. When adjusted for all other covariates, the highest quintile of COVID-19
anxiety remained significantly and strongly associated with all somatic symptoms, except
cardiopulmonary symptoms. The strongest association was with the fatigue subscale of
the PHQ-15.
That the effect for COVID-19 anxiety remained even when controlling for screening
positive for GAD is an important discovery because it suggests that the anxiety that people
are experiencing because of this pandemic is a unique contributor to the somatic problems
that they are suffering from. There is, therefore, potential for additional strain on health
service providers if individuals seek help for these complaints. A public healthmessage that
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Table 1. Descriptive statistics and correlations for all study variables
Age
Gender
(Female) Income
Health
Problem GAD-7 ≥ 10
COVID-19
Anxiety
PHQ:
Pain
PHQ:
Gastro
PHQ:
Cardio
PHQ:
Fatigue
PHQ
total
Gender (female) .261***
Income .068** .158***
Health problem .112** .040 .072*
GAD-7 ≥ 10 .237*** .104*** .119*** .103**
COVID_19 Anxiety .064** .113*** .053* .085* .200***
PHQ: Pain .105*** .023 .105*** .127*** .298*** .112***
PHQ: Gastro .242*** .097*** .090*** .131*** .365*** .129*** .633***
PHQ: Cardio .197*** .069* .050* .135*** .340*** .072** .642*** .704***
PHQ: Fatigue .143*** .137*** .088*** .139*** .384*** .166*** .553*** .614*** .495***
PHQ total .210*** .055* .098*** .155*** .411*** .140*** .835*** .896*** .853*** .770***
Mean/N (%) 45.446 1,047 347 438 67.724 .942 1.140 .634 1.001 3.718
SD/(%) 15.901 (51.9%) (17.1%) (21.6%) 24.596 1.337 1.693 1.431 1.182 4.767
Note. *p < .05; **p < .01; ***p < .001.
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explains to the public that the stress, worry, and anxiety they are feeling about the current
pandemic can manifest in increased levels of physical/somatic problems, particularly
fatigue, pain, and gastrointestinal discomfort, may be helpful in alleviating unnecessary
worry among thepublic and reducing strain on thehealth systemduring this crisis situation.
Of course, any suchpublic healthmessagemust also stress that individualswithpre-existing
health problems, particularly those experiencing cardiopulmonary problems as these
symptomswere unrelated toCOVID-19 anxiety andmay be related to other life-threatening
conditions, should seek appropriatemedical care if their physiological symptoms change in
any way. Furthermore, these findings suggest there may be value in implementing
psychological measures of COVID-19 anxiety in primary care facilities for those presenting
with non-specific and possibly psychosomatic problems.
This study had some limitations. First, our measure of COVID-19 anxiety has not been
previously validated. Second, the temporal ordering of the variables cannot be
established, and so the potential problem of reverse causation cannot be ignored. Third,
the PHQ-15 subscales include a relatively small number of items, and this limits the
variability of the scale scores. This may have resulted in attenuated correlations and
regression coefficients.
Conflicts of interest
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Table 2. Unstandardized regression coefficients from models predicting PHQ-15 Scale and Subscale
Scores
Pain Gastro Cardio Fatigue Total scale
Model 1
COVID-19 anxiety
Quintile 1 – – – – –
Quintile 2 0.140 0.339** 0.231 0.178* 0.889**
Quintile 3 0.189* 0.340** 0.119 0.281*** 0.931**
Quintile 4 0.181* 0.289** 0.064 0.267** 0.801*
Quintile 5 0.427*** 0.594*** 0.251* 0.590*** 1.863***
R2 .011* .012** .004 .027*** .015**
Model 2
COVID-19 anxiety
Quintile 1 – – – – –
Quintile 2 0.103 0.249* 0.164 0.122 0.637*
Quintile 3 0.141 0.251* 0.058 0.196** 0.647*
Quintile 4 0.121 0.230* 0.014 0.179* 0.544
Quintile 5 0.232* 0.327** 0.058 0.337*** 0.954**
Control variables
Age 0.004* 0.019*** 0.013*** 0.005** 0.041***
Gender (female) 0.074 0.021 0.305*** 0.123* 0.234
Income 0.065** 0.052* 0.022 0.028 0.167*
Health problem 0.262** 0.395*** 0.360*** 0.238** 1.255***
GAD-7 ≥ 10 0.858*** 1.243*** 1.059*** 0.971*** 4.131***
R2 .103*** .172*** .152*** .169*** .198***
Note. *p < .05; **p < .01; ***p < .001.
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